Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021

Publisher Name :
Date: 31-Oct-2021
No. of pages: 69
Inquire Before Buying

Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2021, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism (Male Health).

- The pipeline guide reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary (Hypogonadotropic) Hypogonadism - Overview
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
AbbVie Inc
Diurnal Group Plc
IASO BioMed Inc
Marius Pharmaceuticals LLC
Merck & Co Inc
Mereo Biopharma Group Plc
NHTherapeutics Inc
Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rifene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products
Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones
Featured News & Press Releases
Oct 11, 2021: Phase 1 data for DITEST published in European Journal of Endocrinology
Jan 28, 2021: Marius Pharmaceuticals announces Co-CEOs Himanshu H. Shah and Shalin Shah to drive growth ahead of anticipated FDA action of its lead asset, KYZATREX
Jan 05, 2021: Marius Pharmaceuticals submits New Drug Application to U.S. FDA for next-generation oral testosterone replacement therapy in male patients with hypogonadism
Jul 30, 2020: Diurnal Group announces positive DITEST regulatory meeting with US FDA
May 21, 2020: Marius Pharmaceuticals announces issuance of two key patents protecting its proprietary oral testosterone therapy
Jan 15, 2019: Mereo BioPharma: BGS-649 Phase 2b data to be Presented at ENDO 2019
Dec 17, 2018: Mereo BioPharma announces positive results from the safety extension study to the phase 2b clinical trial of BGS-649 for the treatment of hypogonadotropic hypogonadism in obese men
Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism
Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


List of Tables
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by AbbVie Inc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Diurnal Group Plc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by IASO BioMed Inc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Marius Pharmaceuticals LLC, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by NHTherapeutics Inc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, 2021
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, 2021

List of Figures
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
  • Global Drugs for Vulvovaginal Candidiasis Market Insights and Forecast to 2028
    Published: 21-Jan-2022        Price: US 4900 Onwards        Pages: 114
    Drugs for Vulvovaginal Candidiasis market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Drugs for Vulvovaginal Candidiasis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Cream - Pessary - Other Segment by Application......
  • Global Bacterial Vaginosis Drug Market Insights and Forecast to 2028
    Published: 18-Jan-2022        Price: US 4900 Onwards        Pages: 118
    Bacterial Vaginosis Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Bacterial Vaginosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Rx - OTC Segment by Application - Hospital......
  • Global Contraceptives Market Insights and Forecast to 2028
    Published: 17-Jan-2022        Price: US 4900 Onwards        Pages: 118
    Contraceptives market is segmented by Type and by End User. Players, stakeholders, and other participants in the global Contraceptives market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by End User for the period 2017-2028. Segment by Type - Pills - Injectable - Condoms - Vaginal Rings - IUDs - Subdermal Implants - Others......
  • Global Bacterial Vaginosis Drug Market Size, Status and Forecast 2022
    Published: 10-Jan-2022        Price: US 3900 Onwards        Pages: 120
    Bacterial Vaginosis Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bacterial Vaginosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type - Rx - OTC Segment b......
  • Global Contraceptives Market Research Report 2022 Professional Edition
    Published: 07-Jan-2022        Price: US 2890 Onwards        Pages: 143
    The global Contraceptives market was valued at 175.48 Million USD in 2021 and will grow with a CAGR of 2.6% from 2021 to 2027, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, S......
  • Global Drugs for Vulvovaginal Candidiasis Market Outlook 2022
    Published: 05-Jan-2022        Price: US 2900 Onwards        Pages: 111
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Cream - Pessary - Other Segment by Application - Hospital & Clinic - Pharmacy......
  • Therapeutics for Women's Health: Technologies and Global Markets
    Published: 05-Jan-2022        Price: US 5500 Onwards        Pages: 258
    Report Scope: This report is an analytical business tool that comprehensively evaluates the global market for women's health therapeutics. The format of the study is organized around the following topics - - Detailed study around women's diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS. - Disease incidence and prevalence. - Regulatory structure of pharmaceutical industry. - Market characterization, unmet need, m......
  • Cervical Intraepithelial Neoplasia (CIN) (Women's and Male Health) - Drugs in Development, 2021
    Published: 30-Dec-2021        Price: US 2000 Onwards        Pages: 335
    Cervical Intraepithelial Neoplasia (CIN) (Women's and Male Health) - Drugs in Development, 2021 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2021, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape. Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by a......
  • Female Contraception (Women's and Male Health) - Drugs in Development, 2021
    Published: 30-Dec-2021        Price: US 2000 Onwards        Pages: 128
    Female Contraception (Women's and Male Health) - Drugs in Development, 2021 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Drugs In Development, 2021, provides an overview of the Female Contraception (Women's Health) pipeline landscape. Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contra......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs